Close Menu

NEW YORK (GenomeWeb) – Biocept said today that it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately 990,000 shares of its common stock at a price of $2.25 per share, resulting in gross proceeds of approximately $2.2 million.

Maxim Group is acting as the lead placement agent and Dawson James Securities is co-placement agent for the offering, which is expected to close on or about January 23, subject to the satisfaction of customary closing conditions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.